Table 2.

Adjusteda OR (95% confidence interval) of the association between statin use and prostate cancer according to statin type

Any statinAtorvastatinbCerivastatinbFluvastatinbLovastatinbPravastatinbRosuvastatinbSimvastatinb
Ever use0.96 (0.90–1.03)1.00 (0.93–1.08)1.01 (0.82–1.24)1.18 (0.89–1.56)0.95 (0.74–1.21)0.82 (0.71–0.96)0.99 (0.88–1.12)1.00 (0.90–1.11)
Period of use (years prior to the index date)c
Never useref.ref.ref.ref.ref.ref.ref.ref.
2–51.00 (0.93–1.08)1.00 (0.92–1.09)1.34 (0.97–1.85)1.31 (0.90–1.92)0.93 (0.66–1.31)0.97 (0.79–1.18)1.02 (0.89–1.17)1.00 (0.87–1.14)
6–100.95 (0.86–1.05)0.93 (0.82–1.05)0.94 (0.68–1.31)0.72 (0.43–1.18)1.17 (0.78–1.76)0.90 (0.70–1.15)0.94 (0.74–1.19)1.04 (0.87–1.23)
11–201.03 (0.87–1.21)1.21 (0.98–1.49)0.97 (0.63–1.49)1.44 (0.73–2.83)0.63 (0.33–1.20)0.60 (0.40–0.89)0.71 (0.08–6.07)1.10 (0.83–1.45)
Duration of use (years)
Never useref.ref.ref.ref.ref.ref.ref.ref.
<10.97 (0.88–1.07)1.01 (0.90–1.12)0.98 (0.77–1.25)1.65 (1.14–2.37)0.75 (0.48–1.18)0.83 (0.65–1.04)1.01 (0.85–1.20)1.03 (0.88–1.22)
10.96 (0.84–1.09)1.14 (0.98–1.32)1.07 (0.73–1.57)0.88 (0.44–1.77)1.06 (0.63–1.77)0.82 (0.56–1.19)0.87 (0.66–1.14)0.88 (0.68–1.14)
2–40.97 (0.88–1.07)0.92 (0.81–1.04)N/A0.74 (0.35–1.54)1.00 (0.64–1.57)0.81 (0.60–1.09)1.14 (0.92–1.40)0.93 (0.76–1.13)
5+0.94 (0.84–1.06)1.00 (0.86–1.16)N/A0.72 (0.30–1.70)1.11 (0.66–1.86)0.84 (0.59–1.19)0.68 (0.43–1.08)1.14 (0.91–1.42)
Relative time of use (% of follow-up)
Never useref.ref.ref.ref.ref.ref.ref.ref.
1–90.94 (0.85–1.04)1.03 (0.92–1.15)1.08 (0.85–1.38)1.62 (1.08–2.42)0.72 (0.45–1.16)0.82 (0.63–1.06)0.90 (0.75–1.07)1.02 (0.86–1.22)
10–240.97 (0.88–1.08)1.02 (0.90–1.15)1.12 (0.70–1.78)0.90 (0.48–1.69)1.23 (0.80–1.89)0.79 (0.58–1.07)1.05 (0.85–1.28)0.92 (0.75–1.12)
25–490.93 (0.84–1.03)0.91 (0.80–1.04)N/A0.53 (0.24–1.14)0.93 (0.59–1.46)0.82 (0.60–1.10)0.92 (0.66–1.27)0.96 (0.79–1.16)
50+0.96 (0.82–1.13)0.96 (0.74–1.26)N/A1.84 (0.52–6.48)1.17 (0.57–2.41)0.95 (0.57–1.58)N/A1.34 (0.97–1.87)
Average annual dose (DDD)
Never useref.ref.ref.ref.ref.ref.ref.ref.
1–1820.96 (0.90–1.03)1.00 (0.92–1.08)1.00 (0.82–1.23)1.17 (0.88–1.55)0.96 (0.75–1.23)0.87 (0.74–1.02)1.00 (0.88–1.13)0.98 (0.88–1.10)
183–3650.98 (0.83–1.14)1.04 (0.83–1.31)N/AN/A0.73 (0.20–2.67)0.52 (0.31–0.86)0.63 (0.30–1.33)1.11 (0.82–1.51)
366–5460.92 (0.63–1.34)0.53 (0.28–1.01)N/AN/AN/A1.08 (0.27–4.32)1.20 (0.22–6.69)1.80 (0.92–3.51)
547+1.10 (0.61–1.98)4.14 (1.37–12.54)N/AN/A1.89 (0.12–30.43)0.91 (0.07–11.64)N/A1.27 (0.48–3.35)
Total dosage (DDD)
Never useref.ref.ref.ref.ref.ref.ref.ref.
1–1191.02 (0.90–1.16)1.06 (0.92–1.21)0.64 (0.39–1.05)1.40 (0.91–2.15)0.79 (0.47–1.34)0.90 (0.65–1.24)1.19 (0.94–1.50)1.11 (0.91–1.36)
120–4790.96 (0.86–1.07)1.05 (0.93–1.19)1.13 (0.86–1.50)1.25 (0.78–2.01)1.02 (0.67–1.54)0.74 (0.54–1.03)0.83 (0.66–1.03)0.93 (0.76–1.13)
480–1,1990.94 (0.85–1.05)0.91 (0.80–1.03)1.15 (0.79–1.68)1.10 (0.53–2.27)1.03 (0.65–1.64)0.81 (0.60–1.10)1.02 (0.82–1.27)0.90 (0.73–1.12)
1,200+0.94 (0.85–1.05)0.98 (0.86–1.12)N/A0.59 (0.24–1.46)0.90 (0.53–1.55)0.85 (0.65–1.10)0.97 (0.76–1.23)1.05 (0.87–1.26)
  • Abbreviations: DDD, defined daily dose (the assumed average maintenance dose per day for a drug used for its main indication in adults; the DDD is 20 mg for atorvastatin, 0.2 mg for cerivastatin, 60 mg for fluvastatin, 45 mg for lovastatin, 30 mg for pravastatin, 10 mg for rosuvastatin, and 30 mg for simvastatin); N/A, not applicable.

  • aAdjusted for the matching variables (age, regional health authority of residence, and length of drug use coverage), income quintile, number of physician visits in the 5-year period before the index date, screening indicator, chronic cardiovascular disease (excluding hypertension), diabetes, and ever use of non-statin lipid-lowering drugs, metformin, other oral hypoglycemic drugs, insulin, aspirin, and non-aspirin NSAIDs.

  • bAlso adjusted for use of the other individual statins.

  • cAlso adjusted for use of that statin in the other periods.